Skip to main content

ONCY

Stock
Health Care
Biotechnology

Performance overview

ONCY Price
Price Chart

Forward-looking statistics

Beta
1.01
Risk
72.34%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Company info

SectorHealth Care
IndustryBiotechnology
Employees30
Market cap$79.2M

Fundamentals

Enterprise value$40.0M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity15.40

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.29
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+2.4
Credit+5.9
Liquidity-2.9
Inflation+2.4
Commodities-0.7
Interest Rates-1.7

Valuation

Dividend yield0.00%
PEG Ratio-3.07
Price to sales
P/E Ratio-3.07
Enterprise Value to Revenue
Price to book12.27

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research (March 5, 2025)
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer

Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer. Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Benzinga (May 20, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free